89bio falls as RBC downgrades to 'sector perform', cuts PT
U.S. STOCKS ON THE MOVE-Canadian Solar, Domino's, tech stocks
U.S. STOCKS ON THE MOVE-Dollar General, J.B. Hunt, Bristol-Myers
89Bio down on pricing $150 mln stock offering
Brief: 89Bio Announces Upsized Pricing Of $150 Mln Public Offering Of Common Stock And Pre-Funded Warrants
Brief: 89Bio Inc Announces Proposed Underwritten Public Offering Of Common Stock And Pre-Funded Warrants
U.S. STOCKS ON THE MOVE-Korro Bio, Arrowhead Pharma, Structure Therapeutics
U.S. STOCKS ON THE MOVE-Nuvei, SilverSun Technologies, RedHill Biopharma
U.S. STOCKS ON THE MOVE-ONEOK, Jabil, Spotify
89bio up on plans to advance NASH drug study after positive FDA feedback
Brief: 89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024
Brief: 89Bio Announces Positive Long-Term Data From The ENLIVEN Phase 2B Trial Of Pegozafermin In Patients With Nonalcoholic Steatohepatitis
U.S. RESEARCH ROUNDUP-American Financial Group, EverCommerce, Texas Instruments
U.S. STOCKS ON THE MOVE-Hyatt Hotels, Walmart, Maxeon
U.S. STOCKS ON THE MOVE-Olema Pharma, Akamai Technologies, US banks
89bio falls as rival Akero's NASH drug fails in mid-stage study
U.S. STOCKS ON THE MOVE-PepsiCo, Electronic Arts, Honeywell
89bio falls as rival Akero's NASH drug fails in mid-stage study
89bio rises on FDA's 'breakthrough therapy' for NASH treatment